Therapeutic strategies that target insulin/AMPK signaling and/or multi-TKI inhibitors that target ROS, ALK, KIT, FAK, TIE2, SRC, etc., may specifically target the tumor biology of these poorest-prognosis patients. Here, KIT is linked to neoplasm.